Cadila Healthcare Intends to Licence Phibro’s Poultry Vaccine
INDIA - Zydus Cadila and Phibro Animal Health Corporation announced their intention to enter into a long-term arrangement to license Phibro’s innovative poultry vaccine technologies and know-how to a new vaccine manufacturing facility to be built by Zydus Cadila.
6 July 2017
3 minute read
By: According to India Info Line, Phibro Animal Healthcare is a diversified global developer, manufacturer and marketer of a broad range of animal health and mineral nutrition products for use in the production of poultry, swine, dairy, beef cattle and aquaculture.
The share of Cadila Healthcare on the NSE was trading higher at Rs 2.25 per share at Rs 519.40 per share, gains of 0.4 per cent at 1035 hours. It has delivered 55 per cent returns in a period of one-year and has outperformed the BSE Sensex and BSE Healthcare indices over the same time period.
Stock view:
Cadila Healthcare Ltd is currently trading at Rs 519.45, up by Rs 3 or 0.58 per cent from its previous closing of Rs 516.45 on the BSE.
The scrip opened at Rs 525 and has touched a high and low of Rs 525 and Rs 519.4 respectively. So far 185674(NSE+BSE) shares were traded on the counter. The current market cap of the company is Rs 52871.19 crore.
The BSE group 'A' stock of face value Rs 1 has touched a 52 week high of Rs 558 on 12 June 2017 and a 52-week low of Rs 328.9 on 5 July 2016. Last one week high and low of the scrip stood at Rs 532.15 and Rs 508.35 respectively.
The promoters' holding in the company stood at 74.79 per cent while Institutions and Non-Institutions held 17.14 per cent and 8.07 per cent respectively.
The stock is currently trading above its 50 DMA.
